Home › Free Stock Grades › TSHA
Taysha Gene Therapies, Inc. (TSHA) Stock Grade
TSHA · Healthcare
C
Market Cap
$1.6B
P/E Ratio
—
Revenue Growth (YoY)
+17.3%
Net Margin
-1115.3%
Return on Equity
—
Dividend Yield
None
About Taysha Gene Therapies, Inc.'s fundamentals
Taysha Gene Therapies is a biotechnology company with a market capitalization of $1.6 billion that generated revenue growth of 17.3% year-over-year. However, the company operates at a significant loss, with a net margin of -1115.3%, reflecting substantial expenses relative to its revenue base. The company does not currently pay a dividend, and traditional profitability metrics like P/E ratio and return on equity are not applicable given its unprofitable status.